Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy’s to ship omeprazole

This article was originally published in The Tan Sheet

Executive Summary

Dr. Reddy's Laboratories will enter the proton pump inhibitor market as early as July, the Hyderabad, India-based firm announces June 9. It says FDA approved its abbreviated new drug application for omeprazole 20.6 mg after AstraZeneca filed a claim challenging Dr. Reddy's product (1"The Tan Sheet" March 23, 2009, p. 7). The first shipment will go out in the second quarter of 2010. The heartburn relief product will go head to head with Perrigo's omeprazole, which has 40 percent of the OTC PPI market (2"The Tan Sheet" Feb. 9, 2009, p. 12)

You may also be interested in...



Dr. Reddy’s Competition For Perrigo’s Omeprazole Delayed Six Months

Private label leader Perrigo should have an additional six months without competition from Dr. Reddy's against the firm's top-selling OTC product, the proton pump inhibitor omeprazole

Perrigo’s Record OTC Sales Tempered By Rising Costs Of Doing Business

Record OTC drug sales helped boost Perrigo's revenue 29 percent in its latest earnings period, but the rising costs of doing business dragged down margins and forced the company to lower its fiscal 2009 earnings guidance

Sales Already Growing As Vascepa Secures Cardio Approval

Company forecasts 2020 sales as high as $700m after regulator grants broad label.

Topics

UsernamePublicRestriction

Register

PS103010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel